Structure, Distribution, and Genetic Profile of α-Synuclein and Their Potential Clinical Application in Parkinson’s Disease

다국어 초록 (Multilingual Abstract)

Parkinson’s disease (PD), the second most common neurodegenerative disorder after Alzheimer’s disease, is characterized by the loss of nigral dopaminergic neurons. PD leads to a series of clinical symptoms, including motor and non-motor disturbances. α-synuclein, the major component of Lewy bodies, is a hallmark lesion in PD. In this review, we concentrate on presenting the latest research on the structure, distribution, and function of α-synuclein, and its interactions with PD. We also summarize the clinic applications of α-synuclein, which suggest its use as a biomarker, and the latest progress in α-synuclein therapy.

참고문헌 (Reference)

1 Kiely AP, "α-synucleinopathy associated with G51D SNCA mutation:a link between Parkinson’s disease and multiple system atrophy?" 125 : 753-769, 2013

2 Peelaerts W, "α-synuclein strains cause distinct synucleinopathies after local and systemic administration" 522 : 340-344, 2015

3 Guella I, "α-synuclein genetic variability: a biomarker for dementia in Parkinson disease" 79 : 991-999, 2016

4 Spillantini MG, "alpha-synuclein in filamentous inclusions of Lewy bodies from Parkinson’s disease and dementia with Lewy bodies" 95 : 6469-6473, 1998

5 Wang G, "Variants in the SNCA gene associate with motor progression while variants in the MAPT gene associate with the severity of Parkinson’s disease" 24 : 89-94, 2016

6 Mollenhauer B, "Total CSF α-synuclein is lower in de novo Parkinson patients than in healthy subjects" 532 : 44-48, 2013

7 Zarranz JJ, "The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia" 55 : 164-173, 2004

8 Kasten M, "The many faces of alpha-synuclein mutations" 28 : 697-701, 2013

9 Kalinderi K, "The genetic background of Parkinson’s disease : current progress and future prospects" 134 : 314-326, 2016

10 Duda JE, "The expression of alpha-, beta-, and gamma-synucleins in olfactory mucosa from patients with and without neurodegenerative diseases" 160 : 515-522, 1999

11 Ostrerova-Golts N, "The A53T alpha-synuclein mutation increases iron-dependent aggregation and toxicity" 20 : 6048-6054, 2000

12 Dehay B, "Targeting α-synuclein : therapeutic options" 31 : 882-888, 2016

13 Devos D, "Targeting chelatable iron as a therapeutic modality in Parkinson’s disease" 21 : 195-210, 2014

14 Salahuddin P, "Structure of amyloid oligomers and their mechanisms of toxicities : targeting amyloid oligomers using novel therapeutic approaches" 114 : 41-58, 2016

15 Gallea JI, "Structural insights into amyloid oligomers of the Parkinson disease-related protein α-synuclein" 289 : 26733-26742, 2014

16 Bousset L, "Structural and functional characterization of two alpha-synuclein strains" 4 : 2575-, 2013

17 Michell AW, "Skin and platelet alpha-synuclein as peripheral biomarkers of Parkinson’s disease" 381 : 294-298, 2005

18 Del Tredici K, "Review : sporadic Parkinson’s disease : development and distribution of α-synuclein pathology" 42 : 33-50, 2016

19 Markopoulou K, "Reduced expression of the G209A alpha-synuclein allele in familial Parkinsonism" 46 : 374-381, 1999

20 Wolff M, "Quantitative thermophoretic study of disease-related protein aggregates" 6 : 22829-, 2016

21 Shi M, "Plasma exosomal α-synuclein is likely CNS-derived and increased in Parkinson’s disease" 128 : 639-650, 2014

22 Fuchs J, "Phenotypic variation in a large Swedish pedigree due to SNCA duplication and triplication" 68 : 916-922, 2007

23 Adler CH, "Peripheral synucleinopathy in early Parkinson’s disease : submandibular gland needle biopsy findings" 31 : 250-256, 2016

24 Lesage S, "Parkinson’s disease: from monogenic forms to genetic susceptibility factors" 18 : R48-R59, 2009

25 Jankovic J, "Parkinson’s disease: clinical features and diagnosis" 79 : 368-376, 2008

26 Rodríguez-Leyva I, "Parkinson disease and progressive supranuclear palsy : protein expression in skin" 3 : 191-199, 2016

27 Lotia M, "New and emerging medical therapies in Parkinson’s disease" 17 : 895-909, 2016

28 Ferrer I, "Neuropathology and neurochemistry of nonmotor symptoms in Parkinson’s disease" 2011 : 708404-, 2011

29 Braak H, "Neuroanatomy and pathology of sporadic Parkinson’s disease" 201 : 1-119, 2009

30 Besong-Agbo D, "Naturally occurring α-synuclein autoantibody levels are lower in patients with Parkinson disease" 80 : 169-175, 2013

31 Polymeropoulos MH, "Mutation in the alpha-synuclein gene identified in families with Parkinson’s disease" 276 : 2045-2047, 1997

32 Beach TG, "Multi-organ distribution of phosphorylated alpha-synuclein histopathology in subjects with Lewy body disorders" 119 : 689-702, 2010

33 이준성, "Mechanism of Anti-α-Synuclein Immunotherapy" 대한파킨슨병및이상운동질환학회 9 (9): 14-19, 2016

34 Hall S, "Longitudinal measurements of cerebrospinal fluid biomarkers in Parkinson’s disease" 31 : 898-905, 2016

35 Iwanaga K, "Lewy body-type degeneration in cardiac plexus in Parkinson’s and incidental Lewy body diseases" 52 : 1269-1271, 1999

36 Lesage S, "Large-scale screening of the Gaucher’s disease-related glucocerebrosidase gene in Europeans with Parkinson’s disease" 20 : 202-210, 2011

37 Stuendl A, "Induction of α-synuclein aggregate formation by CSF exosomes from patients with Parkinson’s disease and dementia with Lewy bodies" 139 (139): 481-494, 2016

38 Desplats P, "Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein" 106 : 13010-13015, 2009

39 Papadimitriou A, "Hadjigeorgiou GM, Bordoni A, Sciacco M, Napoli L, et al. Partial depletion and multiple deletions of muscle mtDNA in familial MNGIE syndrome" 51 : 1086-1092, 1998

40 Ruffmann C, "Gut feelings about α-synuclein in gastrointestinal biopsies: biomarker in the making?" 31 : 193-202, 2016

41 Schapira AH, "Glucocerebrosidase in Parkinson’s disease : insights into pathogenesis and prospects for treatment" 31 : 830-835, 2016

42 Schapira AH., "Glucocerebrosidase and Parkinson disease:Recent advances" 66 (66): 37-42, 2015

43 Braak H, "Gastric alpha-synuclein immunoreactive inclusions in Meissner’s and Auerbach’s plexuses in cases staged for Parkinson’s disease-related brain pathology" 396 : 67-72, 2006

44 Raiss CC, "Functionally different α-synuclein inclusions yield insight into Parkinson’s disease pathology" 6 : 23116-, 2016

45 Krüger R, "Familial parkinsonism with synuclein pathology : clinical and PET studies of A30P mutation carriers" 56 : 1355-1362, 2001

46 Masliah E, "Effects of alpha-synuclein immunization in a mouse model of Parkinson’s disease" 46 : 857-868, 2005

47 Kiely AP, "Distinct clinical and neuropathological features of G51D SNCA mutation cases compared with SNCA duplication and H50Q mutation" 10 : 41-, 2015

48 Zhu ZJ, "Differential interaction between iron and mutant alpha-synuclein causes distinctive Parkinsonian phenotypes in Drosophila" 1862 : 518-525, 2016

49 Zhu B, "Development of stem cellbased therapies for Parkinson’s disease" 126 : 955-962, 2016

50 Bergström AL, "Development of passive immunotherapies for synucleinopathies" 31 : 203-213, 2016

51 El-Agnaf OM, "Detection of oligomeric forms of alpha-synuclein protein in human plasma as a potential biomarker for Parkinson’s disease" 20 : 419-425, 2006

52 Valera E, "Combination therapies: the next logical step for the treatment of synucleinopathies?" 31 : 225-234, 2016

53 Woulfe JM, "Colonic mucosal α-synuclein lacks specificity as a biomarker for Parkinson disease" 85 : 834-, 2015

54 Visanji NP, "Colonic mucosal a-synuclein lacks specificity as a biomarker for Parkinson disease" 84 : 609-616, 2015

55 Lebouvier T, "Colonic biopsies to assess the neuropathology of Parkinson’s disease and its relationship with symptoms" 5 : e12728-, 2010

56 Papapetropoulos S, "Clinical phenotype in patients with alpha-synuclein Parkinson’s disease living in Greece in comparison with patients with sporadic Parkinson’s disease" 70 : 662-665, 2001

57 Nishioka K, "Clinical heterogeneity of alpha-synuclein gene duplication in Parkinson’s disease" 59 : 298-309, 2006

58 Gwinn K, "Clinical features, with video documentation, of the original familial lewy body parkinsonism caused by α-sy-nuclein triplication (Iowa kindred)" 26 : 2134-2136, 2011

59 Bostantjopoulou S, "Clinical features of parkinsonian patients with the alpha-synuclein(G209A)mutation" 16 : 1007-1013, 2001

60 Sekine T, "Clinical course of the first Asian family with Parkinsonism related to SNCA triplication" 25 : 2871-2875, 2010

61 Spira PJ, "Clinical and pathological features of a Parkinsonian syndrome in a family with an Ala53Thr alpha-synuclein mutation" 49 : 313-319, 2001

62 Tokutake T, "Clinical and neuroimaging features of patient with early-onset Parkinson’s disease with dementia carrying SNCA p.G51D mutation" 20 : 262-264, 2014

63 Barker RA, "Cell-based therapies for Parkinson disease-past insights and future potential" 11 : 492-503, 2015

64 Ibáñez P, "Causal relation between alpha-synuclein gene duplication and familial Parkinson’s disease" 364 : 1169-1171, 2004

65 Schneider SA, "Can we use peripheral tissue biopsies to diagnose Parkinson’s disease? A review of the literature" 23 : 247-261, 2016

66 Kang JH, "CSF biomarkers associated with disease heterogeneity in early Parkinson’s disease : the Parkinson’s Progression Markers Initiative study" 131 : 935-949, 2016

67 Taguchi K, "Brain region-dependent differential expression of alpha-synuclein" 524 : 1236-1258, 2016

68 Skogseth RE, "Associations between cerebrospinal fluid biomarkers and cognition in early untreated Parkinson’s disease" 5 : 783-792, 2015

69 Näsström T, "Antibodies against alphasynuclein reduce oligomerization in living cells" 6 : e27230-, 2011

70 Shahaduzzaman M, "Anti-human α-synuclein N-terminal peptide antibody protects against dopaminergic cell death and ameliorates behavioral deficits in an AAV-α-synuclein rat model of Parkinson’s disease" 10 : e0116841-, 2015

71 Gustot A, "Amyloid fibrils are the molecular trigger of inflammation in Parkinson’s disease" 471 : 323-333, 2015

72 Appel-Cresswell S, "Alpha-synuclein p.H50Q, a novel pathogenic mutation for Parkinson’s disease" 28 : 811-813, 2013

73 Singleton AB, "Alpha-synuclein locus triplication causes Parkinson’s disease" 302 : 841-, 2003

74 Chartier-Harlin MC, "Alpha-synuclein locus duplication as a cause of familial Parkinson’s disease" 364 : 1167-1169, 2004

75 Malek N, "Alpha-synuclein in peripheral tissues and body fluids as a biomarker for Parkinson’s disease-a systematic review" 130 : 59-72, 2014

76 Chung SJ, "Alpha-synuclein in gastric and colonic mucosa in Parkinson’s disease : limited role as a biomarker" 31 : 241-249, 2016

77 Shannon KM, "Alpha-synuclein in colonic submucosa in early untreated Parkinson’s disease" 27 : 709-715, 2012

78 Ahn TB, "Alpha-synuclein gene duplication is present in sporadic Parkinson disease" 70 : 43-49, 2008

79 Atik A, "Alpha-synuclein as a biomarker for Parkinson’s Disease" 26 : 410-418, 2016

80 Klettner A, "Alpha synuclein and crystallin expression in human lens in Parkinson’s disease" 31 : 600-601, 2016

81 Krüger R, "Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson’s disease" 18 : 106-108, 1998

82 Bonilla-Ramirez L, "Acute and chronic metal exposure impairs locomotion activity in Drosophila melanogaster : a model to study Parkinsonism" 24 : 1045-1057, 2011

83 Conway KA, "Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson’s disease: implications for pathogenesis and therapy" 97 : 571-576, 2000

84 Proukakis C, "A novel α-synuclein missense mutation in Parkinson disease" 80 : 1062-1064, 2013

85 Markopoulou K, "A Greek-American kindred with autosomal dominant, levodopa-responsive parkinsonism and anticipation" 38 : 373-378, 1995